Your browser is no longer supported. Please, upgrade your browser.
Settings
ARNA Arena Pharmaceuticals, Inc. daily Stock Chart
ARNA [NASD]
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.47 Insider Own0.59% Shs Outstand242.55M Perf Week5.56%
Market Cap368.68M Forward P/E- EPS next Y-0.33 Insider Trans0.00% Shs Float241.11M Perf Month-7.88%
Income-109.60M PEG- EPS next Q-0.13 Inst Own59.10% Short Float8.83% Perf Quarter-26.92%
Sales39.80M P/S9.26 EPS this Y-211.10% Inst Trans-0.60% Short Ratio7.40 Perf Half Y-56.70%
Book/sh0.34 P/B4.47 EPS next Y26.70% ROA-35.00% Target Price5.50 Perf Year-65.92%
Cash/sh0.75 P/C2.03 EPS next 5Y- ROE-119.80% 52W Range1.30 - 5.12 Perf YTD-20.00%
Dividend- P/FCF- EPS past 5Y31.20% ROI-89.20% 52W High-70.31% Beta-0.84
Dividend %- Quick Ratio4.00 Sales past 5Y28.90% Gross Margin68.60% 52W Low16.92% ATR0.15
Employees325 Current Ratio4.20 Sales Q/Q11.00% Oper. Margin- RSI (14)44.50 Volatility11.44% 11.22%
OptionableYes Debt/Eq0.84 EPS Q/Q-120.00% Profit Margin- Rel Volume0.62 Prev Close1.50
ShortableYes LT Debt/Eq0.80 EarningsFeb 29 AMC Payout- Avg Volume2.88M Price1.52
Recom2.70 SMA20-3.15% SMA50-15.43% SMA200-48.38% Volume1,778,273 Change1.33%
Nov-11-15Reiterated RBC Capital Mkts Sector Perform $5 → $2
Oct-28-15Reiterated WallachBeth Buy $6 → $4
May-12-15Reiterated WallachBeth Buy $8 → $6
Jan-23-15Initiated RBC Capital Mkts Sector Perform $5
Aug-07-14Reiterated WallachBeth Buy $9 → $8
Nov-15-13Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Market Perform $4.50
Oct-25-10Reiterated Barclays Capital Underweight $3 → $2
Sep-20-10Reiterated UBS Neutral $7 → $2
Sep-17-10Downgrade Davenport Buy → Neutral
Sep-14-10Downgrade Barclays Capital Equal Weight → Underweight $4 → $3
Aug-23-10Reiterated UBS Neutral $3.50 → $7
Jul-16-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1
Jul-02-10Reiterated UBS Buy $40 → $38
Feb-04-10Upgrade Rodman & Renshaw Mkt Underperform → Mkt Perform
Dec-17-09Initiated Jefferies & Co Hold $4
Sep-21-09Downgrade Leerink Swann Outperform → Mkt Perform $6
Sep-18-09Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $3
Sep-15-09Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Aug-18-09Initiated JMP Securities Mkt Perform
Feb-09-16 10:23AM  Here's Why Arena Pharmaceuticals Lost 17% of Its Value in January at Motley Fool
Feb-08-16 08:00AM  Biotechnology Stocks Technical Review -- MannKind, Array BioPharma, Arena Pharma, and Chimerix Accesswire
Jan-20-16 03:33PM  Former US president Jimmy Carter Says His Brain Cancer Has Disappeared Accesswire +7.74%
Jan-19-16 10:17AM  Bioelectronic-Medicine Leader Endonovo Therapeutics, Inc. Begins 2016 on a Strong Note Accesswire -6.06%
Jan-13-16 04:25PM  Arena, Boehringer Ingelheim Ink Deal, Schizophrenia in Focus
Jan-12-16 05:19PM  [$$] Arena Pharma Shares Rise on Collaboration Pact With Boehringer at The Wall Street Journal +8.28%
04:55PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
04:05PM  Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to Advance Research in Schizophrenia PR Newswire
Jan-07-16 01:02PM  This Company is Up +400% in a Month Accesswire -6.86%
12:04PM  Arena Pharmaceuticals Ends 2015 On a Sour Note: Can It Recover in 2016? at Motley Fool
08:15AM  CEL-SCI Corp (CVM) Shows Strength: Stock Moves Up 8.3%
08:00AM  Arena Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-06-16 08:00AM  Biotechnology Equity Picks - Arena Pharma, uniQure, Cytokinetics, and Curis Accesswire -5.91%
Jan-05-16 05:05PM  Teva/Active Biotech Halt High Doses of Laquinimod for MS
01:50PM  Pfizer & Merck KGaA Partner with Syndax for Ovarian Cancer
Jan-04-16 08:05AM  Pluristem Therapeutics (PSTI) in Focus: Stock Rises 14.1%
Dec-30-15 10:23AM  The Worst 3 Biotech Stocks for 2016 at Motley Fool
08:02AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : December 30, 2015
Dec-29-15 09:30AM  New Strong Buy Stocks for December 29th
Dec-23-15 08:00AM  Biotechnology Equities Update -- Arena Pharma, Compugen, ChemoCentryx, and Concert Pharma Accesswire
Dec-22-15 09:30AM  New Strong Buy Stocks for December 22nd
Dec-21-15 10:10AM  Arena Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers +6.84%
08:00AM  Technical Report on Biotechnology Stocks -- Arena Pharma, Cara Therapeutics, Corcept Therapeutics, and Ignyta Accesswire
Dec-18-15 09:30AM  New Strong Buy Stocks for December 18th
Dec-16-15 08:00AM  Biotechnology Equities Scrutiny -- Arena Pharma, Lion Biotechnologies, Bellicum Pharma, and ANI Pharma Accesswire +5.59%
Dec-14-15 08:39AM  Why Arena Pharmaceuticals (ARNA) Could Beat Earnings Estimates Again
Dec-08-15 01:17PM  ARENA PHARMACEUTICALS INC Financials
01:12PM  Orexigen Therapeutics' Stock Dropped 28% in November: Can It Recover? at Motley Fool
Dec-07-15 01:11PM  Arena Pharmaceuticals, Inc. Value Analysis (NASDAQ:ARNA) : December 7, 2015 -7.73%
12:29PM  Bluebird Bio Crashes After Clinical Trial Update
09:37AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 7, 2015
09:30AM  New Strong Buy Stocks for December 7th
Dec-05-15 10:15AM  Top 6 BioPharma Movers of the Week at 24/7 Wall St.
Dec-04-15 04:57PM  Orexigen Therapeutics, Inc.'s Stock Loses Weight on Downgrade at Motley Fool -5.91%
02:08PM  Why Arena Pharmaceuticals, Inc. Bulked Up in November at Motley Fool
Dec-03-15 09:30AM  New Strong Buy Stocks for December 3rd
07:00AM  Why Axovant Sciences Skyrocketed 56% in November at Motley Fool
Dec-02-15 03:20PM  Zafgen Plunges On Death In Obesity-Drug Trial at Investor's Business Daily
11:22AM  Can the Rally in Arena Pharmaceuticals (ARNA) Shares Continue?
Dec-01-15 05:05PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events -5.44%
04:32PM  Arena (ARNA)/Eisai's Belviq XR NDA Accepted for Review
11:06AM  Here's Why Arena Pharmaceuticals' Stock Briefly Spiked Today at Motley Fool
09:30AM  New Strong Buy Stocks for December 1st
08:00AM  Eisai and Arena Pharmaceuticals Announce Completion of Enrollment in BELVIQ® (lorcaserin HCI) CAMELLIA-TIMI 61 Study PR Newswire
Nov-30-15 07:40PM  Why Ambarella, Arena Pharmaceuticals, and ITC Holdings Jumped Today at Motley Fool +11.16%
01:35PM  Arena Pharma Soars on FDA Approval
08:37AM  How Arena Pharma (ARNA) Stock Stands Out in a Strong Industry
08:00AM  Eisai and Arena Pharmaceuticals Announce FDA Acceptance of New Drug Application for Extended Release Formulation of Lorcaserin PR Newswire
Nov-27-15 09:05AM  Nextera Energy Partners LP (NEP): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-25-15 05:35PM  Drugmakers drop weight
Nov-24-15 12:07PM  Is Smart Money Losing Interest in Uniqure NV (QURE)? at Insider Monkey
08:00AM  Arena Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare Conference PR Newswire
Nov-19-15 08:00AM  Arena Pharmaceuticals to Host Analyst & Investor Day on December 3rd PR Newswire
Nov-17-15 09:04AM  Arena Rose 14% in XBIs Small-Cap Space
08:05AM  Health-Care Defies Economic Conditions and Moves to New Highs - Broad Street Alerts Accesswire
Nov-12-15 11:00AM  3 Dangerous Stocks at Motley Fool
08:30AM  How it All Plays Out - Research on SunOpta, Arena Pharmaceuticals, AngioDynamics and Del Taco Restaurants Accesswire
Nov-11-15 10:34AM  Arena 3Q Loss Narrower-Than-Expected, Belviq in Focus -5.26%
Nov-10-15 09:29PM  Edited Transcript of ARNA earnings conference call or presentation 10-Nov-15 10:00pm GMT -7.77%
05:05PM  Amira Nature Foods, AlarmCom, Flotek Moving In Tuesday's After Hours Session
05:00PM  Arena Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today
04:20PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:09PM  Arena Pharmaceuticals reports 3Q loss
04:00PM  Arena Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update PR Newswire
07:07AM  Q3 2015 Arena Pharmaceuticals Inc Earnings Release - After Market Close
Nov-06-15 12:20PM  Why Orexigen Therapeutics, Inc.'s Stock Is Losing Weight Today at Motley Fool
10:16AM  Newlink Genetics Announced Positive Results in 3Q15
Nov-04-15 08:00AM  Arena Pharmaceuticals to Host Third Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10 PR Newswire +7.32%
Nov-03-15 08:30AM  Direction of Market Influences - Research on Cerus, Arena Pharmaceuticals, Walter Investment Management and AngioDynamics Accesswire -5.09%
Nov-02-15 05:04PM  Axovant to start pair of dementia drugs trials at Financial Times +14.29%
08:00AM  Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at 2015 Annual Obesity Week Meeting PR Newswire
Oct-30-15 01:35PM  Will Arena's (ARNA) Q3 Loss be Narrower-than-Expected?
12:25PM  Here's Why Arena Pharmaceuticals, Inc. Is Struggling Today at Motley Fool
08:19AM  Why biotech could be on the verge of a rebound
08:17AM  How it All Plays Out - Research on Arena Pharmaceuticals, XOMA, Ekso Bionics and Cellceutix Accesswire
Oct-29-15 04:36PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events -7.14%
08:00AM  Arena Pharmaceuticals Initiates a Phase 1b Clinical Trial of APD371 PR Newswire
Oct-27-15 06:09PM  Arena Pharmaceuticals to lay off 35 pct of U.S. workers
04:15PM  Arena Pharmaceuticals to lay off 35 pct of U.S. workforce
04:14PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities
04:00PM  Arena Pharmaceuticals Announces New Strategic Focus and Cost Reduction Plan PR Newswire
08:00AM  Arena Pharmaceuticals Issued Additional Patent Covering BELVIQ® (lorcaserin HCl) by United States Patent and Trademark Office PR Newswire
Oct-19-15 03:44PM  IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Claims Against Arena Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm Business Wire
Oct-17-15 08:20AM  What's Behind Arena Pharmaceuticals' Volatility Lately? at Motley Fool
Oct-16-15 05:54PM  Glancy, Prongay & Murray LLP Commences Investigation on Behalf of Arena Pharmaceuticals, Inc. Investors Business Wire
12:23PM  Why Zafgen Plummeted Today at Motley Fool
Oct-07-15 04:21PM  Harwood Feffer LLP Announces Investigation of Arena Pharmaceuticals, Inc. PR Newswire
Oct-05-15 05:26PM  Monday's After-Hours Movers Led By Du Pont, Arena Pharma, Illumina & Container Store Group +8.59%
04:32PM  Arena Pharma shares tick higher as CEO retires at MarketWatch
04:15PM  Arena Pharmaceuticals Announces Retirement of President and CEO PR Newswire
Sep-30-15 04:43PM  10 Worst NASDAQ Biotech Stocks in the Third Quarter at TheStreet
Sep-24-15 08:00AM  Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at Upcoming Medical Meetings PR Newswire
Sep-18-15 09:21PM  Why Hasn't Orexigen Launched Its Obesity Drug in Europe Yet? at Motley Fool -5.42%
12:40PM  3 Investing Myths, Debunked! at Motley Fool
Sep-11-15 05:23PM  Short on cash? 4 stocks under $5 +5.54%
Sep-10-15 12:00PM  2 Questions Investors Need to Ask About Biogen's Latest Deal at Motley Fool +5.45%
Sep-09-15 09:24AM  Biogen Takes on Celgene With New Autoimmune License Deal at TheStreet -6.88%
Sep-05-15 07:11AM  Arena Pharmaceuticals Lost a Third of Its Value in August -- Here's Why at Motley Fool
Sep-03-15 08:00AM  Arena Pharmaceuticals to Present at the Wells Fargo 2015 Healthcare Conference PR Newswire
Aug-31-15 05:56PM  Westaim completes Arena Transactions CNW Group
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. It is also developing a portfolio of programs in various therapeutic areas, including cardiovascular, central nervous system, and metabolic diseases. Its products under development include Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, including potentially pulmonary arterial hypertension that is in Phase II clinical trials. The company's products under development also comprise APD334, an modulator of the sphingosine 1-phosphate subtype 1 receptor for the treatment of a various autoimmune diseases, which has completed Phase I single-ascending dose trials; APD371, an agonist of the cannabinoid receptor 2 that is in Phase I clinical trials intended for the treatment of pain and fibrotic diseases; and Temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I clinical trials. In addition it manufactures drug products under a toll manufacturing agreement for Siegfried AG. Arena Pharmaceuticals, Inc. has collaboration with Boehringer Ingelheim. The company was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WOODS RANDALL EDirectorMar 30Option Exercise1.3976,268105,719121,380Apr 01 06:58 PM
WOODS RANDALL EDirectorMar 30Sale4.4976,268342,25345,112Apr 01 06:58 PM
SPECTOR STEVEN WEVP, General Counsel & SecMar 17Option Exercise1.5170,000105,803198,039Mar 18 05:45 PM
SPECTOR STEVEN WEVP, General Counsel & SecMar 17Sale5.0070,000350,000128,039Mar 18 05:45 PM
LIEF JACKPresident and CEOMar 03Option Exercise1.49125,000186,250622,189Mar 04 05:54 PM